Although in vitro transport/inhibition studies are commonly performed on impure drug candidates to screen for pharmacokinetic properties in early development, quantitative guidelines concerning acceptable impurity levels are lacking. The broad goal was to derive models for the effect of impurity on transport and inhibition studies and identify the maximum allowable impurity level that does not bias assay results. Models were derived, and simulations were performed to assess the impact of impurity on substrate properties K t and J max and inhibition K i . Simulation results were experimentally challenged with a known amount of impurity, using the intestinal bile acid transporter as a model system. For substrate uptake studies, glycocholate served as substrate and was contaminated with either a very strong, strong, or moderate impurity (i.e., taurolithocholate, chenodeoxycholate, or ursodeoxycholate, respectively). For inhibition studies, taurocholate and glycocholate together was the substrate/inhibitor pair, where glycocholate was contaminated with taurolithocholate. There was high agreement between simulation results and experimental observations. It is not surprising that, in the inhibition assay, potent impurity caused test compound to appear more potent than the true potency of the test compound (i.e., reduced inhibitory K i ). However, results in the transport scenario surprisingly indicated that potent impurity did not diminish test compound potency but, rather, increased substrate potency (i.e., reduced Michaelis-Menten substrate K t ). In general, less than 2.5% impurity is a reasonable target, provided the impurity is less than 10-fold more potent than test compound. Study results indicate that careful consideration of possible impurity effect is needed when quantitative structureactivity relationship analysis cannot explain high compound potency from transport or inhibition studies.
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Transport and inhibition studies are routinely performed in early development to screen for absorption, distribution, metabolism, and excretion (ADME). For example, a current project in our laboratory concerns the targeting of an intestinal transporter for drug delivery purposes (Balakrishnan and Polli, 2006) . The transporter is the human apical sodium-dependent bile acid transporter (hASBT). ADME considerations in this project motivate the screening for substrates and inhibitors of hASBT to construct a quantitative structure-activity relationship (QSAR) model for inhibitors and substrates of this transporter. Test compounds are currently being synthesized to evaluate the chemical structural features that allows for hASBT inhibition, as well as translocation by hASBT (Balakrishnan et al., 2006a) .
However, test compounds in early development often contain chemical impurities, including intermediates that bear structural similarity to the target test compound. The presence of such impurities has potential to affect the results of pharmacologic assays, including ADME screening results. Guidelines on compound purity are not provided in the Journal of Pharmacology and Experimental Therapeutics. Since January 2007, the Journal of Medicinal Chemistry now requires that key target compounds possess a purity of 98% or more. However, well developed guidelines and their rationale regarding an acceptable level of impurity, based on possible impurity impact on assay results during early development, are surprisingly lacking. Guidance on impurity effects on ADME screening studies would be helpful.
The present study concerns two types of ADME transport studies: inhibition studies and transport/uptake studies. It is presumed in a competitive binding study (e.g., inhibition study) that impurity with a potency greater than that of test compound may cause the test compound to appear more potent than it is in actuality. This expectation was found to ylammonium chloride, pH 6.8. Because ASBT is sodium-dependent, studies using sodium-free buffer allowed for the measurement of passive uptake. Kinetics of hASBT-mediated GCA uptake (n ϭ 3) was assessed at different donor concentrations (1-200 M spiked with 0.2 Ci/ml [ 14 C]GCA) in the presence and absence of impurity. When impurity was present, each GCA donor solution was contaminated with TLCA, CDCA, or UDCA (i.e., impurity) to yield a mole fraction of impurity, X i , of 2, 4, 6, 8, and 10%, respectively. K i of these impurities was obtained from GCA-uptake inhibition studies (see below).
At the end of the assay, active uptake was stopped by washing the cells three times with chilled sodium-free buffer. Cells were then lysed with 0.25 ml of 1 N NaOH overnight, allowing for complete evaporation, and reconstituted with 0.50 ml of 0.5 N HCl. Cell lysate was counted for associated radioactivity using an LS6500 liquid scintillation counter (Beckman Instruments, Inc., Fullerton, CA).
Inhibition Assay. To characterize hASBT binding affinities, cisinhibition studies of TCA or GCA uptake were conducted as described. Cells were exposed to donor solutions containing relevant substrate (2.5 M TCA ϩ 0.5 Ci/ml [ 3 H]TCA or 5 M GCA ϩ 0.2 Ci/ml [ 14 C]GCA) and inhibitor (1-200 M) for 10 min. GCA inhibition of TCA was measured in the absence and presence of impurity. When impurity was present, each GCA donor solution was contaminated with TLCA (i.e., impurity) to yield a mole fraction of impurity, X j , of 2, 4, 6, 8, and 10%, respectively. TLCA inhibition of TCA uptake was also measured to obtain K j (see below). After 10 min, donor solution was removed; cells were washed three times with chilled sodium-free buffer, lysed, and counted for associated radioactivity (i.e., TCA). Inhibition data were analyzed in terms of inhibition constant K i as described below.
Simulation of Substrate Transport: Impurity Effect on Substrate Flux. To assess the impact of impurity on substrate flux, simulations were performed using eqs. 1 and 2 (see Appendix A) for scenarios with and without impurity, respectively. Equations 1 and 2 denote the impurity-present model and the impurity-absent model, respectively, for transport/uptake studies.
Flux in the presence of impurity (J X i ) was calculated using eq. 1 over a range of K t , X i , and K i values. Substrate K t was 5, 50, and 500 M; substrate concentration (S) was one-tenth of K t . Impurity level 
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(X i ) was varied from 0 to 10% mole fraction, with greater sampling for larger K t scenarios. K i was 0.05, 0.5, 5, 50, and 500 M, respectively. J max , P ABL , and P p were fixed to 0.5 pmol/cm 2 /s, 70 ϫ 10 Ϫ6 cm/s, and 0.5 ϫ 10 Ϫ6 cm/s, respectively, in all cases (Balakrishnan et al., 2007) . Equation 2 (i.e., flux without impurity, J) is eq. 1 when X i ϭ 0. The ratio J X i /J was calculated as a metric for impurity effect on flux and plotted against X i . It is important to note that S was the actual assigned substrate concentration in donor; the concentration of substrate and impurity (when X i Ͼ 0) was greater than S.
Simulation of Substrate Transport: Impurity Effect on K t and J max Estimates. To assess impurity effect on K t and J max , estimates from transport studies, simulated flux data were generated from impurity-present model (eq. 1). Across the simulations, K t was 5, 50, or 500 M, whereas J max was 0.5 pmol/cm 2 /s. Because the aim of these simulation studies is to measure impurity effect on bias on estimated K t and J max parameter fits, these K t values (i.e., 5, 50, and 500 M) and J max value (i.e., 0.5 pmol/cm 2 /s) are denoted as "true K t " and "true J max ", respectively. In simulations, S was 1/20, 1/10, 1/5, 1/2, 1, 2, 5, 10, and 20 ϫ K t to assure saturation of active transport. P ABL and P p were 70 ϫ 10 Ϫ6 and 0.5 ϫ 10 Ϫ6 cm/s, respectively. Simulated flux data were subsequently fitted to impurityabsent model (eq. 2) for each unique condition (i.e., unique K t , K i , and X i scenario). Nonlinear regression was used to simultaneously estimate K t and J max using SigmaPlot 8.0 (SPSS Inc, Chicago, IL). In all cases, r 2 ϭ 1.000. Results are discussed in terms of resulting bias in K t and J max , due to impurity, relative to "true K t " and "true J max " values that were employed in simulating flux data. K t estimates were plotted against impurity level for each "true K i " level. Similar plots were graphed for J max estimates. Estimation error in K t (or J max ) that exceeded 20% was considered unacceptably biased.
Simulation of Inhibition Studies: Impurity Effect on K i Estimate. To simulate impurity influence on K i estimate, eq. 3 (see Appendix B) was used to simulate inhibition profiles, where inhibitor was contaminated with impurity. Equation 3 is the impurity-present inhibition model.
It should be noted that, in contrast to transport simulations above where K i is the inhibition constant of the impurity that contaminates the substrate, K i is the unbiased inhibition constant of the inhibitor (i.e., the value to be measured in the inhibition study). K j is the unbiased inhibition constant of the impurity that contaminates the inhibitor. Impurity is present in inhibitor at level X j . Across simulations, K t , J max , P ABL , and P p were fixed to be 5 M, 0.5 pmol/cm 2 /s, 70 ϫ 10 Ϫ6 cm/s, and 0.5 ϫ 10 Ϫ6 cm/s, respectively, which reflects active TCA transport across hASBT-MDCK monolayers (Balakrishnan et al., 2007) . K i was 0.05, 0.5, 5, 50, and 500 M. Inhibitor concentration was 1/20, 1/10, 1/5, 1/2, 1, 2, 5, 10, and 20 ϫ K i . Impurity K j was 0.5, 5, and 50 M. An entire inhibition profile was generated for each level of impurity (X j ), which ranged from 0 to 10% mole fraction. Each inhibition profile (i.e., unique K i , K j , and X j scenario) was fitted to impurity-absent inhibition model (eq. 4; see Appendix B) using nonlinear regression. Only K i was estimated, whereas all other parameters assumed their true values. In all cases, r 2 ϭ 1.000, with the exception for one extreme inhibition study simulation (K i ϭ 500 M) where r 2 Ͻ 0.6.
Results are discussed in terms of resulting bias in K i , due to impurity, relative to true K i values that were employed in simulating inhibition profile. K i estimates were plotted against impurity level for each true K j level. Estimation error in K i that exceeded 20% was considered unacceptably bias.
Impurity Effect on Active Uptake Kinetic Estimates: Experimental Evidence. A series of uptake experiments where model substrate GCA was contaminated with model impurity TLCA, CDCA, or UDCA were conducted to confirm simulation predictions. These bile acids were selected for several reasons. Previous data from our laboratory have shown GCA K t to be 11.0 Ϯ 1.9 M. K i values for TLCA, CDCA, and UDCA were 0.50 Ϯ 0.05, 1.94 Ϯ 0.17, and 22.6 Ϯ 3.0 M, respectively (Balakrishnan et al., 2006b) . TLCA, CDCA, and UDCA were chosen as impurities because of their high structural similarity to the substrate probe (i.e., GCA) and because they represent cases that were K t /K i Ϸ 100, 10, and 1, respectively.
The uptake format was chosen to keep P p at a minimum since high passive permeability (i.e., low monolayer integrity on transport format) was found to hinder proper evaluation of impurity impact on active transport parameter estimates. For uptake studies, P ABL was set to 1.5 ϫ 10 Ϫ4 cm/s in analyzing experimental data (Balakrishnan et al., 2007) . Given that the impurity-present uptake and inhibition models are based on the assumption of competitive inhibition between the compound of interest and the impurity, a Dixon's analysis was performed to investigate the inhibition mechanism of TLCA on GCA uptake.
Analysis of Experimental Data from Uptake Studies. Experimental data from GCA uptake studies (X i ϭ 0 -10%, with and without sodium) and from impurity-mediated inhibition of GCA uptake were combined and fitted simultaneously to eqs. 1, 2, 4, and 5 in WinNonlin 5.2 (Pharsight, Mountain View, CA) using nonlinear regression to obtain "unbiased" estimates of GCA K t , J max , K i , and P p . Subsequently, values of these unbiased estimates were applied to eq. 1 (i.e., impurity-present uptake model) to simulate GCA-uptake profiles when X i was 2, 4, 6, 8, and 10%, respectively. Predicted "biased" K t and J max were obtained by nonlinear fitting of these subsequent curves to eq. 2.
To challenge the predictive accuracy of the impurity-present model, GCA uptake in presence of impurity was fitted to eq. 2 (i.e., impurity-absent uptake model) to obtain observed biased GCA kinetic estimates, K t and J max , for each level of impurity mole fraction, X i . Predicted bias and observed bias were compared.
Analysis of Experimental Data from Inhibition Studies.
Compared to data analysis of uptake studies, the same approach was taken to challenge the impurity-present inhibition model and analyze impurity effect on GCA K i . GCA inhibition of TCA uptake (with and without TLCA as impurity) and TLCA inhibition profile were fitted simultaneously to eqs. 3 and 4, respectively, using nonlinear regression to obtain unbiased estimates of K i , K j , J max , and P p . TCA K t was obtained from parallel uptake studies. Subsequently, values of these unbiased estimates were applied to eq. 3 (i.e., impuritypresent inhibition model) to simulate GCA inhibition profiles when X j was 2, 4, 6, 8, and 10%, respectively. Predicted biased K i was obtained by nonlinear fitting of these curves to eq. 4.
To challenge the predictive accuracy of the impurity-present inhibition model, GCA inhibition studies in presence of impurity were fitted to eq. 4 (impurity-absent inhibition model) to obtain observed biased GCA K i for each level of impurity mole fraction, X j . Predicted bias and observed bias were compared.
Results
Simulation results are presented first, followed by supporting experimental observations (Table 1) .
Simulation of Substrate Transport: Impurity Effect on Substrate Flux. Simulations indicate that impurity generally decreased substrate flux across cell monolayers. For example, Fig. 1 illustrates the decrease in flux of a moderate substrate (i.e., K t ϭ 50 M) in the presence of increasing amount of impurity, particularly for the more potent impurities. A 20% decrease in flux was observed when the impurity was a strong inhibitor (i.e., K i ϭ 0.5 M; open circles) and present at approximately 3.5% molar fraction level. Meanwhile, only a 0.5% mole fraction of a most strong inhibitor (i.e., K i ϭ 0.05 M; closed circles) was needed to cause a 20% decrease in flux. Simulations covering a broader range of K t values showed similar trends, including the susceptibility of weaker substrates to more pronounced impurity effects (see Supplemental Fig. a) . Figure 2 illustrates the effect of impurity potency on flux profile of a strong substrate (K t ϭ 5 M). Impurity level was X i ϭ 2%. In general, greater inhibition potency of impurity resulted in reduced substrate flux. For example, a most strong impurity (K i ϭ 0.05 M) reduced substrate flux approximately 3-fold at 50 M substrate concentration. Of note, an impurity whose K i is equal to the substrate's K t (i.e., K i ϭ 5 M) had no marked effect. Meanwhile, the impurities with 10-(i.e., K i ϭ 0.5 M) and 100-fold (i.e., 0.05 M) greater potency provided notable flux reduction. Qualitatively, similar results were observed for the effect of impurity potency on moderate (K t ϭ 50 M) and weak (K t ϭ 500 M) substrate (data not shown), although the effects are more dramatic.
Simulation of Substrate Transport: Impurity Effect on K t and J max Estimates. The impact of impurity on K t and J max was assessed by fitting simulated data from eq. 1 (i.e., impurity-present model) onto eq. 2 (i.e., impurity-absent model). This approach mimics the common scenario in early discovery where impurity is present, but data analysis assumes no impurity. Bias in kinetic estimates was negative to reduce the estimated values of K t and J max . Whereas this effect in J max is intuitive, this effect on K t would appear to be unexpected. As described above, impurity reduced substrate flux but resulted in the substrate to appear as a substrate with greater affinity than it truly possesses (i.e., estimated K t Ͻ true K t ). Figure 3 illustrates estimated K t as a function of impurity level for a strong substrate (5 M). Bias was deemed to occur when impurity caused more than a 20% error in estimate. From Fig. 3 , the impurity potency needed to be at least 10-fold higher than that of the substrate to cause bias. When K t /K i ϭ 10, the impurity level needed to cause bias was always approximately 2.5% mole fraction. For example, X i ϭ 2.5% lead the estimated K t to be 4 M when K t /K i ϭ 10. Simulations covering a broader range of K t values showed similar trends, including the susceptibility of weaker substrates to impurity effects (see Supplemental Fig. b ) Table 2 summarizes the relationship between K t /K i ratio and the necessary X i to cause bias. In Table 2 , regardless whether the potency of the substrate was 5, 50, or 500 M, the K t /K i ratio of 10 always resulted in K t bias, although bias required the impurity level to be at least 2.5% mole fraction. When K t /K i ϭ 100, approximately 0.25% impurity caused 20% bias, depending on the K t value. However, when K t /K i ϭ 1 or less, bias did not manifest for even X i ϭ 10%.
Regarding effect of impurity on J max , plots of estimated J max versus X i were identical to those in Fig. 3 . It is interesting that X i levels had the same relative effect on J max as on K t (Supplemental Fig. c) . Although presented for impurity effect on K t bias, Table 2 equally applies for J max bias. For Fig. 1 . Decrease in total flux of substrate across a monolayer due to presence of impurity. Total flux of a substrate (J) was simulated using eq. 2 (i.e., impurity-absent model) for K t level of 50 M. Equation 1 (i.e., impurity-present model) modeled the influence of impurity on substrate total flux (J X i ). When the impurity present, X i , varied from 0 to 10% over five different levels of K i (0.05, 0.5, 5, 50, and 500 M, respectively), the impurity effect was assessed by the ratio of fluxes in the presence and absence of impurity (i.e., ratio of J X i versus J). The ratio J X i /J was 1 when no impurity was present and then decreased consistently as impurity level increased. The drop in total flux was more dramatic as the potency of the inhibitor increased. Whereas the effect on J max is intuitive, this effect of impurity to reduce K t would appear to be unexpected. K t is often interpreted as an affinity parameter, such that impurity effects would result in the substrate to appear as a substrate with greater affinity than it truly possesses (i.e., estimated K t Ͻ true K t ). Figure 2 illustrates the basis for this effect. Figure 2 was generated for X i ϭ 2% for a strong substrate (K t ϭ 5 M). For the scenario K i ϭ 0.5 M (open circles), estimated J max and K t were 0.415 pmol/cm 2 /s and 4.15 M, respectively, which are each 17% less than the true values of 0.5 pmol/cm 2 /s and 5 M, respectively. In this scenario, it can be interpreted that impurity effect to reduce J max estimate causes a proportional effect on K t estimate, vis-à -vis the J max effect. Given that K t is the concentration at half-J max and because impurity reduces apparent J max , impurity reduces apparent K t .
Simulation of Inhibition Studies: Impurity Effect on K i Estimates. In addition to transport studies, inhibition studies are frequently performed in development and design to evaluate the ability of a compound to inhibit the transport of a known substrate. Data are often interpreted as an inhibition constant (K i ). Here, impurity J imp contaminates inhibitor I and competes against I (and substrate) for the same transporter in a noncooperative fashion (see Supplemental  Fig. d) . By virtue of impurity contributing additional inhibition, impurity can produce negative bias in K i estimates from inhibition studies.
The extent of this bias is illustrated in Fig. 4 (substrate K t ϭ 5 M) for a strong inhibitor (K i ϭ 5 M) and shows bias depended on the affinity of the impurity (i.e., K j ) and its mole fraction, X j . For example, a very strong impurity (K j ϭ 0.5 M) at X i ϭ 2.5% caused 20% bias in estimated K i , resulting in apparent K i to be 4 M. Simulations covering a broader range of K i values showed similar trends, including the susceptibility of weaker inhibitors to more pronounced impurity effects (see Supplemental Fig. e) . The impact of impurities on inhibition results mimics the above effect on transport studies. Table 3 summarizes the relationship between K i /K j ratio and the impurity level required to produce bias on K i estimates. Results in Table 3 from inhibition studies mimic results in Table 2 from transport studies, although Table 3 concerns K i /K j ratio, whereas Table 2 concerns K t /K i ratio. In Table 3 , no bias manifested when K i /K j Յ 1, similar to an observation in Table 2 . In addition, for either a strong or moderate inhibitor, K i /K j ϭ 10 resulted in bias when X j was at least 2.5%, similar to an observation in Table 2 . For a moderate inhibitor, X j ϭ 0.6% caused bias in K i when K i /K j ϭ 100.
Impurity Effect on Active Uptake Kinetic Estimates: Experimental Evidence. A series of uptake experiments Fig. 3 . Impact of impurity on K t estimates from transport studies when impurity not considered. K t value was 5 M. The mole fraction of impurity, X i , varied from 0 to 10%. K i values were 0.05 (filled circle), 0.5 (open circle), 5 (filled triangle), 50 (open triangle), or 500 M (filled diamond). Impurity generally reduced estimated K t . An estimated K t of 80% or less than the true K t value was considered unacceptably biased. Impurity level and inhibitory potency each promoted bias. Bias in K t estimates was increasingly sensitive to impurity level when true K t was at least 10-fold larger than K i and was very large when K t was weak while K i was strong. It is interesting that analogous plots for bias in J max followed identical trends (see supplemental data). Strong (K t ϭ 5 M) Յ1 Never a concern when X i Յ 10% 10 Ն2.5% 100 Ն0.5% Moderate (K t ϭ 50 M) Յ1 Never a concern when X i Յ 10% 10 Ն2.5% 100 Ն0.25% 1000 Ն0.1% Weak (K t ϭ 500 M) Յ1 Never a concern when X i Յ 10% 10 Ͼ2.5% 100 Ն0.25% 1000 Trace 10,000 Trace a K t /K i reflects the ratio of the ЉtrueЉ affinity constant of the substrate of interest versus the inhibition constant of its impurity. Fig. 4 . Impact of impurity on K i estimate from inhibition studies when inhibitor contaminated with impurity. K i is inhibition constant of inhibitor. K j is inhibition constant of impurity. Impurity contaminated the inhibitor. True K i value was 5 M. Impurity level was varied from 0 to 10% mole fraction. K j was 0.5 (filled circle), 5 (open circle), and 50 M (filled triangle), respectively. Impurity generally resulted in either no effect or decreased apparent K i . An estimated K i of 80% or less than the true K i was considered unacceptably biased. When present, bias was always negative (i.e., estimated K i less than true K i ). No bias in K i estimate was observed when the ratio K i /K j was 1 or less. However, K i /K j ratios of 10 or higher caused K i bias when impurity level exceeded 2.5%. No fit was obtained for K i 500 M (data not shown). where model substrate GCA was contaminated with model impurities TLCA, CDCA, or UDCA were conducted. GCA K t is approximately 10 M, such that K t /K i for TLCA, CDCA, and UDCA were approximately 100, 10, and 1, respectively (Balakrishnan et al., 2006b) . TLCA was found to be a competitive inhibitor of GCA uptake (Supplemental Fig. f) . Figure 5 shows bias on GCA K t and J max estimates from uptake when TLCA was present as impurity. These estimates were always negatively biased by the presence of TLCA at the entire range of X i studied. Unbiased K t and J max of substrate were 12.6 (Ϯ1.1) M and 0.424 (Ϯ0.041) pmol/ cm 2 /s, whereas TLCA K i was 0.11 (Ϯ0.01) M. When X i ϭ 2%, observed K t and J max estimates of GCA were 3.76 (Ϯ0.87) M and 0.113 (Ϯ0.004) pmol/cm 2 /s, representing an estimation error of 70 and 73% respectively. From Fig. 5A , interpolation predicts that a 0.24% mole fraction of TLCA would produce a 20% bias on GCA K t estimate (experimental K t GCA /K i TLCA ϭ 114), reflecting the high level of agreement between model predictions and observed results (r 2 ϭ 0.979 for K t and 0.995 for J max ).
Identical experiments were performed with GCA contaminated with CDCA as impurity. Unbiased GCA K t and J max were 11.0 (Ϯ1.8) M and 0.153 (Ϯ0.013) pmol/cm 2 /s, respectively, whereas unbiased CDCA K i ϭ 1.39 (Ϯ0.39) M (K t / K i ϭ 7.92). Although CDCA caused negative bias on GCA J max , regardless of impurity load, K t estimates were biased only when X i Ͼ 2%. Figure 6 shows the bias effect of CDCA on GCA K t and J max . Experimentally, a 6% mole fraction of CDCA caused a 20% drop on estimated GCA K t relative to the unbiased value, whereas 4% caused similar estimation error on J max . The ability of the model to predict biased K t estimates was modest (r 2 ϭ 0.806) and good to predict J max (r 2 ϭ 0.908).
Identical studies were also performed with GCA-UDCA as substrate-impurity pair. Unbiased GCA K t was 9.82 (Ϯ0.79) M. Unbiased UDCA K i was 24.2 (Ϯ2.8) M, such that K t / K i ϭ 0.40 for this GCA-UDCA pair. Unlike the above GCA-TLCA and GCA-CDCA pairs, it was not possible to obtain biased estimates for the GCA-UDCA pair due to poor inhibitory potency of the UDCA impurity.
Impurity Effect on Inhibition Constant Estimates: Experimental Evidence. To evaluate the impact of impurity on K i estimates from inhibition assays, GCA-mediated inhibition of TCA uptake was measured in the absence and presence of TLCA as impurity (X j ϭ 0 -10%). Here X j represents the mole fraction of impurity J imp (i.e., TLCA) contaminating inhibitor I (i.e., GCA) (Supplemental Fig. d ). This inhibitor-impurity pair was chosen to represent a K i /K j Ϸ 10 based on previous data (Balakrishnan et al., 2006b) . Figure 7 shows bias on GCA K i estimates as a function of TLCA mole fraction. Unbiased GCA K i was 5.05 (Ϯ0.48) M, whereas unbiased TLCA K j was 0.40 (Ϯ0.04) M (K i /K j ϭ 12.6). TLCA contamination caused negative bias on GCA inhibition constant estimation over the entire range of X j . For example, when TLCA was present at a 2% mole fraction, observed GCA K i estimate was 4.39 (Ϯ0.32) M. Interpolation of predicted data identified a critical X j level of 1.95% to obtain a 20% bias on GCA K i estimation. The impurity-present model predicted observed bias on K i (r 2 ϭ 0.919).
Discussion
Implications for ADME Screening and hASBT Studies. Transport and inhibition studies are routinely performed Most strong (K i ϭ 0.05 M) Յ0.1 Never a concern when X j Յ 10%
Never a concern when X j Յ 10% 10 Ն2.5% Moderate (K i ϭ 50 M) Յ1 Never a concern when X j Ͻ 10% 10 Ն2.5% 100 5 . Impact of taurolithocholate on glycocholate kinetic estimates from uptake studies. Mole fraction of TLCA was varied from 0 to 10%. TLCA contamination produced negative bias on GCA kinetic estimates (i.e., increased "apparent" affinity and decreased "apparent" capacity in A and B, respectively). A 2% mole fraction of TLCA generated approximately 70% error on the estimation of both GCA K t and J max . These experimental observations followed the model predicted trends. Unbiased K t and J max of substrate were 12.6 (Ϯ1.1) M and 0.424 (Ϯ0.041) pmol/cm 2 /s, whereas TLCA K i was 0.11 (Ϯ0.01) M. Data are presented as mean (ϮS.E.M.). S.E.M. bars are smaller than the symbol in B.
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jpet.aspetjournals.org in early development to screen for ADME. A current project in our laboratory concerns the targeting of hASBT for drug delivery purposes (Balakrishnan and Polli, 2006) . ADME considerations motivate the screening for substrates and inhibitors of hASBT to construct a QSAR model for inhibitors and substrates of this transporter.
hASBT (SLC10A2) is a 348 amino acid transmembrane protein that mediates the active uptake of bile acids in the small intestine, playing a critical role in the bile acid enterohepatic recirculation (Hagenbuch and Dawson, 2004) . The total bile acid pool in humans (3-5 g) recirculates several times a day, giving a turnover of 12 to 18 g/day (Hofmann, 1999) . However, no more than 0.5 g are lost in the feces daily, reflecting the high capacity and efficiency of this transporter (Hofmann and Mysels, 1992) . This suggests that some drugs with poor oral absorption may benefit from conjugation to bile acids by utilizing hASBT as carrier to enter the enterocyte. Despite the enormous potential of hASBT as target for bile acid containing prodrugs, only a few examples of its use can be found in the literature (Sievä nen, 2007) . Employing this approach, the oral bioavailability of acyclovir was enhanced in rats via a bile acid conjugate prodrug of acyclovir (Tolle-Sander et al., 2004) . Furthermore, hASBT is a promising pharmacological target, where hASBT inhibitors could lower blood cholesterol (Buchwald et al., 2002) . Hence, hASBT is a target for novel substrates and inhibitors. An understanding of impurity effects on transport and inhibition assays is needed and the subject of this report.
Since January 2007, the Journal of Medicinal Chemistry now requires that key target compounds possess a purity of 98% or more. Results here support this requirement and indicate that, in transport and uptake studies, impurity can cause an underestimation in J max , as well as an underestimation in K t . This impact on apparent K t appears to be surprising, because impurity would cause the apparent affinity of a substrate to be more potent than its true potency. Results of these simulation studies imply that transport studies results that conclude a drug candidate to be a potent substrate merit inspection to assure that impurity is not causing over-favorable results, particularly if a chemical reactant, precursor, or side product is known to be a potent inhibitor.
For example, in employing hASBT as a carrier for drug delivery and a bile acid prodrug where TCA (K i ϭ 5 M) is the targeting moiety, a result of K t ϭ 50 M could reflect several scenarios, such as 1) the target compound to possess K t ϭ 50 M; 2) the target to possess K t ϭ 500 M but also be contaminated with a most strong impurity (K i ϭ 0.05 M) at a level of X i ϭ 0.075%; 3) the target to possess K t ϭ 500 M but also be contaminated with a very strong impurity (K i ϭ 0.5 M) at a level of X i ϭ 0.8%; or 4) the target to possess K t ϭ 500 M but also be contaminated with an impurity (K i ϭ 5 M) at a level of X i ϭ 8%.
Experience to date suggests that scenario "1" would be most likely, which is favorable as the intent is to measure unbiased parameters, but emphasizes that purification methods should be designed to remove critical impurities from target compound. Scenario "2" does not appear likely, because the lowest K i to date is 0.5 M or approximately Fig. 6 . Impact of chenodeoxycholate on glycocholate kinetic estimates from uptake studies. Experimentally, CDCA contamination produced modest negative bias on GCA K t (A) and GCA J max (B), particularly compared to the larger bias shown in Fig. 5 . This more modest level of bias reflects that CDCA impurity is less potent than TLCA impurity in Fig. 5 . However, even a 10% mole fraction of CDCA impurity caused a 50% bias in estimated GCA K t and J max (A and B, respectively). Unbiased K t and J max of GCA substrate were 11.0 (Ϯ1.8) M and 0.153 (Ϯ0.013) pmol/cm 2 /s, whereas CDCA K i was 1.39 (Ϯ0.39) M. Data are presented as mean (ϮS.E.M.). Fig. 7 . Impact of taurolithocholate on glycocholate K i when taurolithocholate was present as impurity. TLCA contamination produced negative bias on GCA apparent affinity. A 4% mole fraction of TLCA caused 34% error in GCA K i estimation. Predicted bias anticipated these experimental observations. Unbiased K i of GCA was 5.05 (Ϯ0.48) M, whereas TLCA K j was 0.40 (Ϯ0.04) M. Data are presented as mean (ϮS.E.M.).
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Gonzá lez and Polli at ASPET Journals on July 8, 2017 jpet.aspetjournals.org 10-fold less potent than required by this scenario. Scenario "4" is not practically possible, because this scenario would require at least 8% impurity by TCA, which will not occur with purification effort. Scenario "3" represents a potentially real and challenging situation, where a relatively small amount (i.e., X i ϭ 0.8%) of most potent impurity (e.g., TLCA with K i ϭ 0.5 M) contaminates the target. However, formation of TLCA from unreacted taurocholate is not expected. Consideration of these scenarios supports a 97.5 to 98% purity level, as long as very potent impurities are not present. For target compounds of high interest, inhibition data showing a drug candidate to be potent inhibitor merit inspection in which impurity is not causing over-favorable results, particularly if a chemical reactant, precursor, or side product is known to be a potent inhibitor.
Results from this study motivates purification methods to eliminate, if not minimize, unreacted bile acid in target bile acid prodrug compounds. Furthermore, in the case of conjugates of highly potent bile acids, enough hydrolytic stability must be assured in the transport/inhibition buffer so that regeneration of the parent-targeting moiety does not occur during the course of the assay. Unfortunately, target compounds that show moderate or weak affinity cannot be completely excluded from potential bias, as small amounts of very strong impurity can bias results and evade conventional detection. Hence, the ultimate benefit of these findings may be the need for careful consideration of impurity effect on transport and inhibition results, particularly when QSAR analysis cannot explain high compound potency.
In conclusion, the present study concerns two types of ADME transport studies: inhibition studies and transport/uptake studies. It is presumed that in a competitive binding study (e.g., inhibition study), impurity with a potency greater than test compound potency may cause test compound to appear more potent than it is in actuality. This expectation was found to be correct here and offers quantitative guidelines. Surprisingly, an expectation that a potent impurity would diminish the apparent potency of a test compound in the uptake assay (i.e., increase Michaelis-Menten K t ) was found in this study to be incorrect. Rather, potent impurity, which reduces test compound flux, resulted in test compound appearing to possess higher substrate affinity (i.e., exhibit a lower K t ). This study provides quantitative guidelines, which are currently lacking, on maximal impurity levels to avoid bias on transporter parameter estimates (i.e., K t , J max , and K i ) in early drug development. Results have implications for other types of early discover assays, such as pharmacologic binding studies.
where X i is mole fraction of impurity in the sample.
Substituting eq. 8 into eq. 6,
The flux in eq. 9 is the flux across a monolayer where solute is both actively and passively translocated but where an impurity inhibits active solute transport. It should be emphasized that S is actual solute concentration. From eq. 9, the monolayer permeability can be considered to be
Given that the flux across a monolayer is in series with the aqueous boundary layer (ABL),
where P app is apparent permeability and P ABL is the permeability of S across the ABL. Substituting eq. 10 into eq. 11,
With impurity present in solute, the apparent flux is J X i ϭ P app ϫ S, such that Impurity Impact on Kinetic Estimates
Equation 14 describes the flux of a solute across a monolayer, in the presence of an ABL, where solute is translocated actively and passively and where impurity inhibits solute active transport.
If no impurity is present or if impurity does not inhibit solute active transport, eq. 14 simplifies to
Equations 14 and 15 are eqs. 1 and 2 under Materials and Methods and represent the impurity-present transport model and impurity-absent transport model, respectively.
